Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 4/20 | 0.34 |
| ▸ | LDHB | P07195 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080696 | 0.89 | LDHA (0.34) | LDHALDHBPPARGPPARAALOX5 | |
| SCHEMBL7075153 | 0.77 | LDHA (0.35) | LDHARIPK1PPARGPPARAALOX5 | |
| SCHEMBL7074205 | 0.73 | UTS2R (0.36) | RIPK1PPARGPPARAALOX5FFAR1 | |
| SCHEMBL7080444 | 0.72 | LDHA (0.35) | LDHA | |
| SCHEMBL7077453 | 0.71 | ESR1 (0.33) | — | |
| SCHEMBL7075204 | 0.71 | UTS2R (0.35) | PPARGPPARAALOX5 | |
| SCHEMBL7074566 | 0.71 | LDHA (0.35) | LDHA | |
| SCHEMBL7079047 | 0.70 | SIGMAR1 (0.35) | — | |
| SCHEMBL7077618 | 0.68 | TLR7 (0.33) | — | |
| SCHEMBL7078827 | 0.68 | DRD2 (0.34) | RIPK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | claimed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | DNPEP, PRSS1, PREP | LDHA 2167/4885LDHB 1995/4885RIPK1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.